Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TVTX on Nasdaq
Shares outstanding
89,403,587
Price per share
$27.87
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
102,161,535
Total reported value
$3,903,877,547
% of total 13F portfolios
0%
Share change
-2,667,207
Value change
+$8,107,644
Number of holders
274
Price from insider filings
$27.87
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% -6.9% $253,331,874 -$17,690,876 10,599,660 -6.5% JANUS HENDERSON GROUP PLC 30 Sep 2025
FMR LLC 12% $403,768,185 10,567,303 FMR LLC 31 Dec 2025
BlackRock, Inc. 7.5% -21% $122,617,344 -$24,357,949 6,689,435 -17% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 6.7% +18% $88,715,388 +$14,507,892 5,994,283 +20% The Vanguard Group 30 Jun 2025
STATE STREET CORP 5.3% $138,466,547 4,756,666 STATE STREET CORPORATION 31 Dec 2025
PERCEPTIVE ADVISORS LLC 4.8% -12% $124,537,820 -$17,973,533 4,278,180 -13% Perceptive Advisors LLC 31 Dec 2025
ARMISTICE CAPITAL, LLC 4.2% -41% $104,899,642 -$82,498,238 3,763,891 -44% Armistice Capital, LLC 31 Dec 2025
Rock Springs Capital Management LP 3.3% -40% $53,545,523 -$37,621,463 2,921,196 -41% Rock Springs Capital Management LP 31 Mar 2025
Woodline Partners LP 2.4% $38,750,646 2,114,056 Woodline Partners LP 31 Dec 2024

As of 31 Dec 2025, 274 institutional investors reported holding 102,161,535 shares of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX). This represents 114% of the company’s total 89,403,587 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 12% 10,511,166 -0.83% 0.18% $401,715,922
FMR LLC 11% 9,617,863 +232% 0.02% $367,498,538
BlackRock, Inc. 8.8% 7,869,352 -2.9% 0.01% $300,687,941
VANGUARD GROUP INC 7.1% 6,309,229 -4.6% 0% $241,075,642
STATE STREET CORP 5.3% 4,756,666 +48% 0.01% $181,752,208
PERCEPTIVE ADVISORS LLC 4.8% 4,278,180 +13% 3% $163,469,258
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 4.2% 3,773,564 0% 0.22% $144,188,000
ARMISTICE CAPITAL, LLC 4.2% 3,763,891 -44% 3.5% $143,818,275
ADAGE CAPITAL PARTNERS GP, L.L.C. 3.3% 2,927,000 -18% 0.17% $111,840,670
RENAISSANCE TECHNOLOGIES LLC 2.5% 2,246,779 +28% 0.13% $85,849,426
Rock Springs Capital Management LP 2.5% 2,210,322 +2.1% 4.3% $84,456,404
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,143,495 +0.26% 0.01% $81,915,213
GOLDMAN SACHS GROUP INC 2.1% 1,868,212 +47% 0.01% $71,384,380
BANK OF AMERICA CORP /DE/ 2.1% 1,850,355 +32% 0.01% $70,702,066
Stephens Investment Management Group LLC 1.9% 1,721,623 +7.6% 0.86% $65,783,215
EMERALD ADVISERS, LLC 1.8% 1,594,184 -26% 1.9% $60,913,771
MORGAN STANLEY 1.6% 1,415,897 +27% 0% $54,101,442
Eversept Partners, LP 1.3% 1,174,968 -17% 2.5% $44,895,527
TWO SIGMA INVESTMENTS, LP 1.3% 1,156,807 +25% 0.07% $44,201,595
D. E. Shaw & Co., Inc. 1.2% 1,094,556 +65% 0.03% $41,822,985
Nuveen, LLC 1.1% 993,613 -7.9% 0.01% $37,965,953
EMERALD MUTUAL FUND ADVISERS TRUST 1.1% 948,459 -21% 1.8% $36,240,618
Driehaus Capital Management LLC 1% 901,404 +27% 0.23% $34,442,647
DEUTSCHE BANK AG\ 0.99% 881,680 -45% 0.01% $33,688,992
Fiera Capital Corp 0.98% 874,053 0.11% $33,397,565

Institutional Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 102,161,535 $3,903,877,547 +$8,107,644 $38.21 274
2025 Q3 100,727,863 $2,407,390,168 +$19,761,610 $23.90 235
2025 Q2 100,531,635 $1,487,836,300 +$12,972,115 $14.80 207
2025 Q1 98,007,579 $1,771,747,554 +$87,075,624 $17.92 214
2024 Q4 95,064,656 $1,655,970,325 +$204,069,962 $17.42 194
2024 Q3 82,734,245 $1,157,476,987 -$64,293,173 $13.99 175
2024 Q2 87,955,117 $723,000,948 +$2,540,410 $8.22 168
2024 Q1 87,706,388 $676,170,447 +$11,374,907 $7.71 172
2023 Q4 85,573,515 $769,316,791 +$27,493,568 $8.99 162
2023 Q3 82,430,217 $736,935,857 -$48,196,261 $8.94 166
2023 Q2 82,714,633 $1,270,488,775 -$85,984,898 $15.36 165
2023 Q1 84,151,882 $1,892,538,812 +$263,849,900 $22.49 171
2022 Q4 72,978,794 $1,535,405,782 +$36,464,951 $21.03 153
2022 Q3 69,779,173 $1,719,469,986 -$2,015,044 $24.64 168
2022 Q2 69,489,567 $1,683,983,339 +$17,370,839 $24.23 166
2022 Q1 69,479,485 $1,789,961,946 +$97,223,694 $25.77 166
2021 Q4 65,477,167 $2,032,139,426 +$61,452,684 $31.04 165
2021 Q3 60,858,590 $1,476,104,164 +$4,235,576 $24.25 145
2021 Q2 60,583,594 $883,983,031 -$73,514,650 $14.59 131
2021 Q1 62,621,768 $1,563,390,183 +$254,685,025 $24.97 147
2020 Q4 52,293,956 $1,423,328,983 +$1,416,953,984 $27.26 135